Tier 1 — highest
Sulforaphane as an adjunctive treatment for irritability in children with autism spectrum disorder: A randomized, double-blind, placebo-controlled clinical trial
Psychiatry and Clinical Neurosciences
2020
74(7):398-405
Bibliography
- PubMed
- PMID 32347624
- Funding
- Funded by Tehran University of Medical Sciences and Health Services, grant 37048.
- Competing interests
- The authors declared no conflict of interest.
Study snapshot
| Design | Randomized, double-blind, placebo-controlled adjunctive trial |
|---|---|
| Model | Children aged 4-12 years with autism spectrum disorder |
| Sample | 60 randomized |
| Intervention | Risperidone plus sulforaphane 50 µmol/day at ≤45 kg or 100 µmol/day at >45 kg versus risperidone plus placebo. |
| Duration | 10 weeks |
| Endpoints | ABC-C Irritability; Hyperactivity/Noncompliance; Lethargy/Social Interaction; Stereotypic Behavior; Inappropriate Speech; Adverse events |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
- Sulforaphane & Autism: What RCTs and the 2025 Meta-Analyses ShowSulforaphane autism evidence reconciled: positive, mixed and null randomized trials plus two 2025 meta-analyses with differing pooled conclusions, doses, safety and limitations.Read analysis
- Sulforaphane Benefits: Human Evidence Ranked by Strength (2026)Sulforaphane benefits ranked by human evidence across 37 papers: bioavailability, pollutant biomarkers, blood sugar, autism, NRF2, H. pylori, cancer and key limitations.Read analysis
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
